Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
Kai Hung Tiong, Li Yen Mah, Chee‐Onn Leong
APOPTOSIS (2013) Vol. 18, Iss. 12, pp. 1447-1468
Open Access | Times Cited: 160

Showing 1-25 of 160 citing articles:

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Melanie A. Krook, Julie W. Reeser, Gabrielle Ernst, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 5, pp. 880-892
Open Access | Times Cited: 256
Covalent Inhibition in Drug Discovery
Avick Kumar Ghosh, Indranil Samanta, Anushree Mondal, et al.
ChemMedChem (2019) Vol. 14, Iss. 9, pp. 889-906
Open Access | Times Cited: 223
Antitumoral activity of quinoxaline derivatives: A systematic review
Marc Montana, Fanny Mathias, Thierry Terme, et al.
European Journal of Medicinal Chemistry (2018) Vol. 163, pp. 136-147
Closed Access | Times Cited: 174
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue, Yukun Li, Xiaojuan Chen, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 116
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
Li Tan, Jun Wang, Junko Tanizaki, et al.
Proceedings of the National Academy of Sciences (2014) Vol. 111, Iss. 45
Open Access | Times Cited: 168
FGF Family: From Drug Development to Clinical Application
Qi Hui, Zi Jin, Xiaokun Li, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 7, pp. 1875-1875
Open Access | Times Cited: 148
Targeting the fibroblast growth factor receptor family in cancer
Niamh Hallinan, Stephen P. Finn, Sinéad Cuffe, et al.
Cancer Treatment Reviews (2016) Vol. 46, pp. 51-62
Closed Access | Times Cited: 109
Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes
Stephen T. Guest, Zachary Kratche, Aliccia Bollig‐Fischer, et al.
Experimental Cell Research (2015) Vol. 332, Iss. 2, pp. 223-235
Closed Access | Times Cited: 106
Long noncoding RNAs and tumorigenesis: genetic associations, molecular mechanisms, and therapeutic strategies
Fan Zhang, Liang Zhang, Caiguo Zhang
Tumor Biology (2015) Vol. 37, Iss. 1, pp. 163-175
Closed Access | Times Cited: 105
Revealing quinquennial anticancer journey of morpholine: A SAR based review
Fatima Arshad, Mohemmed Faraz Khan, Wasim Akhtar, et al.
European Journal of Medicinal Chemistry (2019) Vol. 167, pp. 324-356
Closed Access | Times Cited: 105
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
Dawn Q. Chong, Andrew X. Zhu
Oncotarget (2016) Vol. 7, Iss. 29, pp. 46750-46767
Open Access | Times Cited: 101
Fibroblast Growth Factor Receptor Functions in Glioblastoma
Ana Jimenez‐Pascual, Florian A. Siebzehnrübl
Cells (2019) Vol. 8, Iss. 7, pp. 715-715
Open Access | Times Cited: 100
Therapeutic progression of quinazolines as targeted chemotherapeutic agents
Ranju Bansal, Anjleena Malhotra
European Journal of Medicinal Chemistry (2020) Vol. 211, pp. 113016-113016
Closed Access | Times Cited: 90
Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy
Osama M. Soltan, Mai E. Shoman, Salah A. Abdel‐Aziz, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113768-113768
Closed Access | Times Cited: 87
The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia
Brian Czaya, Christian Faul
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 17, pp. 4195-4195
Open Access | Times Cited: 83
Genetic mutation and biological pathway prediction based on whole slide images in breast carcinoma using deep learning
Hui Qu, Mu Zhou, Zhennan Yan, et al.
npj Precision Oncology (2021) Vol. 5, Iss. 1
Open Access | Times Cited: 78
Molecular therapeutic targets in non-small cell lung cancer
K. Nathan Sankar, Shirish M. Gadgeel, Angel Qin
Expert Review of Anticancer Therapy (2020) Vol. 20, Iss. 8, pp. 647-661
Closed Access | Times Cited: 74
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy
Jason I. Griffiths, Jinfeng Chen, Patrick A. Cosgrove, et al.
Nature Cancer (2021) Vol. 2, Iss. 6, pp. 658-671
Open Access | Times Cited: 60
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Jing Ye, Junhao Wu, Bo Liu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188866-188866
Closed Access | Times Cited: 29
Targeted Glioma Therapy—Clinical Trials and Future Directions
A. B. Shikalov, Igor Koman, Natalya M. Kogan
Pharmaceutics (2024) Vol. 16, Iss. 1, pp. 100-100
Open Access | Times Cited: 12
Recent advances in c-Met-based dual inhibitors in the treatment of cancers
Fanqi Jin, Yi‐Han Lin, Yuan Weidong, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116477-116477
Closed Access | Times Cited: 12
Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis
Rola Saleeb, Fadi Brimo, Mina Farag, et al.
The American Journal of Surgical Pathology (2017) Vol. 41, Iss. 12, pp. 1618-1629
Closed Access | Times Cited: 85
Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases
Mei‐Kuang Chen, Mien‐Chie Hung
FEBS Journal (2015) Vol. 282, Iss. 19, pp. 3693-3721
Open Access | Times Cited: 83
Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling
Angel Qin, Adrienne Johnson, Jeffrey S. Ross, et al.
Journal of Thoracic Oncology (2018) Vol. 14, Iss. 1, pp. 54-62
Open Access | Times Cited: 82
Page 1 - Next Page

Scroll to top